$TRIL Boston Business Journal trillium (Nasdaq: TRIL) raised $117 million late last week in an oversubscribed fundraising, surpassing its initial $75 million goal proceeds from Trillium’s recent fundraising will propel its two main drug candidates through the last round of Phase 1 testing this year and into Phase 2 tests against acute myeloid leukemia, T-cell lymphomas and multiple myeloma. Unlike drugs like Merck Keytruda and Bristol-Myers Opdivo TTI-621, stops a mechanism that cancer cells use to camouflage themselves from the immune system while also signaling the body that it should attack the cells. In tests, between 13% and 29% of patients responded to a low dose of the drug. Tril now testing a higher dose of the treatment to boost that response rate. plans to test TTI-621 in combination with products like Keytruda and Opdivo that target the secondary immune response, known as the adaptive immune system TRIL will look for a partner to commercialize products in Japan and Europe
  • 6
  • 1